[go: up one dir, main page]

PH12019501942A1 - Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor - Google Patents

Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor

Info

Publication number
PH12019501942A1
PH12019501942A1 PH12019501942A PH12019501942A PH12019501942A1 PH 12019501942 A1 PH12019501942 A1 PH 12019501942A1 PH 12019501942 A PH12019501942 A PH 12019501942A PH 12019501942 A PH12019501942 A PH 12019501942A PH 12019501942 A1 PH12019501942 A1 PH 12019501942A1
Authority
PH
Philippines
Prior art keywords
responsive
treatment
biomarkers
cancer patients
identifying cancer
Prior art date
Application number
PH12019501942A
Other languages
English (en)
Inventor
Dirk Brehmer
Lijs Beke
Dana Suzanne Gaffney
Christopher H Moy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PH12019501942A1 publication Critical patent/PH12019501942A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12019501942A 2017-02-27 2019-08-22 Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor PH12019501942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762464006P 2017-02-27 2017-02-27
PCT/EP2018/054644 WO2018154104A1 (fr) 2017-02-27 2018-02-26 Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5

Publications (1)

Publication Number Publication Date
PH12019501942A1 true PH12019501942A1 (en) 2020-06-29

Family

ID=61563368

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501942A PH12019501942A1 (en) 2017-02-27 2019-08-22 Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor

Country Status (23)

Country Link
US (2) US11279970B2 (fr)
EP (1) EP3585904B1 (fr)
JP (1) JP7225106B2 (fr)
KR (1) KR102573149B1 (fr)
CN (1) CN110382707A (fr)
AU (1) AU2018225312B2 (fr)
BR (1) BR112019017466A2 (fr)
CA (1) CA3049739A1 (fr)
CL (1) CL2019002438A1 (fr)
CO (1) CO2019008390A2 (fr)
EA (1) EA201992026A1 (fr)
ES (1) ES2971035T3 (fr)
IL (1) IL268842B2 (fr)
JO (1) JOP20190199B1 (fr)
MA (1) MA47594A (fr)
MX (1) MX2019010150A (fr)
MY (1) MY195860A (fr)
PE (1) PE20191359A1 (fr)
PH (1) PH12019501942A1 (fr)
SG (1) SG11201907607VA (fr)
TN (1) TN2019000212A1 (fr)
UA (1) UA127679C2 (fr)
WO (1) WO2018154104A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
JP6909799B2 (ja) 2016-03-10 2021-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Prmt5阻害剤として使用するための置換ヌクレオシドアナログ
AU2017338269B2 (en) 2016-10-03 2021-03-25 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
WO2018154104A1 (fr) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5
JP2021505583A (ja) * 2017-12-05 2021-02-18 エンジェクス ファーマシューティカル インコーポレイテッド Pmrt5阻害剤としての複素環式化合物
BR112020010815A2 (pt) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
CN120539415A (zh) * 2024-02-21 2025-08-26 复旦大学附属华山医院 一种系统性硬化症生物标志物及其检测方法与应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CN1331326A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
US7144871B2 (en) 2002-02-19 2006-12-05 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (fr) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. Procede de synthese d'un bisdinucleoside cyclique
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
WO2008001101A2 (fr) 2006-06-29 2008-01-03 Astex Therapeutics Limited Combinaisons pharmaceutiques
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
US8962580B2 (en) 2008-09-23 2015-02-24 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
US8323918B2 (en) * 2008-12-12 2012-12-04 University Of South Carolina Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases
SG181703A1 (en) 2009-12-18 2012-07-30 Harvard College Beta-cell replication promoting compounds and methods of their use
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
US9029343B2 (en) 2010-12-03 2015-05-12 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2651885A1 (fr) 2010-12-16 2013-10-23 Abbvie Inc. Composés antiviraux
EP2694524B1 (fr) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides
JP2014530910A (ja) 2011-10-24 2014-11-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited 新規化合物
WO2013151975A1 (fr) 2012-04-02 2013-10-10 Northeastern University Compositions et procédés d'inhibition de méthyltransférases
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
WO2014100716A1 (fr) * 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
EP2975938A4 (fr) 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibiteurs de prmt5 et leurs procédés d'utilisation
CA2935944A1 (fr) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Benzoxazine substituee et composes associes
EP3160477A4 (fr) 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
NZ728162A (en) 2014-07-01 2023-06-30 Takeda Pharmaceuticals Co Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN107278205A (zh) 2015-02-24 2017-10-20 辉瑞大药厂 用作抗癌药的取代的核苷衍生物
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
AU2017338269B2 (en) 2016-10-03 2021-03-25 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
WO2018154104A1 (fr) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5
BR112020010815A2 (pt) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos

Also Published As

Publication number Publication date
PE20191359A1 (es) 2019-10-01
EP3585904C0 (fr) 2023-11-29
CL2019002438A1 (es) 2019-11-29
IL268842A (en) 2019-10-31
US20220205026A1 (en) 2022-06-30
WO2018154104A1 (fr) 2018-08-30
MY195860A (en) 2023-02-24
IL268842B2 (en) 2024-09-01
JOP20190199A1 (ar) 2019-08-27
IL268842B1 (en) 2024-05-01
KR102573149B1 (ko) 2023-08-30
UA127679C2 (uk) 2023-11-29
CA3049739A1 (fr) 2018-08-30
TN2019000212A1 (en) 2021-01-07
AU2018225312B2 (en) 2024-02-08
US11999993B2 (en) 2024-06-04
MX2019010150A (es) 2019-10-21
ES2971035T3 (es) 2024-06-03
EA201992026A1 (ru) 2020-01-24
EP3585904B1 (fr) 2023-11-29
US20200010881A1 (en) 2020-01-09
JP7225106B2 (ja) 2023-02-20
MA47594A (fr) 2020-01-01
US11279970B2 (en) 2022-03-22
KR20190122677A (ko) 2019-10-30
CO2019008390A2 (es) 2019-08-20
JOP20190199B1 (ar) 2023-09-17
JP2020508048A (ja) 2020-03-19
EP3585904A1 (fr) 2020-01-01
SG11201907607VA (en) 2019-09-27
BR112019017466A2 (pt) 2020-03-31
AU2018225312A1 (en) 2019-07-25
CN110382707A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
CR20170104A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
WO2016065349A3 (fr) Arn non codants courts régulateurs de protéines (sprrna) et procédés d'utilisation
HK1231513A1 (zh) 活化素抑制劑應答預測和用於治療的用途
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
MX382266B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
EA201991455A1 (ru) Композиции и способы лечения дефицита альфа-1-антитрипсина
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX388084B (es) Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
MX2020006673A (es) Metodos de tratamiento del cancer mediante el uso de un inhibidor de ataxia-telangiectasia mutada y rad3 (atr).
PH12017501064A1 (en) Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
EA201491780A1 (ru) Мутанты c-raf, придающие резистентность к ингибиторам raf
BR112014027413A2 (pt) biomarcadores para terapia com inibidor de iap
EP4495238A3 (fr) Ciblage de l'egln1 dans le cancer
MX357018B (es) Método de diagnóstico temprano de carcinoma hepatocelular.
UA96069U (uk) Спосіб прогнозування зрощення перелому
PL410049A1 (pl) Sposób wykrywania zwiększonego ryzyka zachorowania na raka skóry oraz zastosowania genotypowego wariantu genu GRHL3
UA96087U (uk) Спосіб прогнозування зрощення перелому